3 July 2020
UK Research and Innovation, Cancer Research UK and industry are investing more than £11 million in an Oxford-led artificial intelligence (AI) research programme to improve the diagnosis of lung cancer and other thoracic diseases.
23 April 2020
Many congratulations to Dr Mark Hill, who has become a Fellow of the Society for Radiological Protection (FSRP).
26 March 2020
UK National Cancer Imaging Translational Accelerator (NCITA) establishes infrastructure for validation and adoption of cancer imaging biomarkers as decision-making tools in clinical trials and NHS practice. Researchers and medical experts from nine world-leading medical imaging centres across the UK come together to form an integrated infrastructure for standardising and validating cancer imaging biomarkers for clinical use.
9 March 2020
Group of Professor Kristijan Ramadan has published an original scientific article in Nature Communications today. The article has the first report of a new autophagy receptor TEX264, which may be involved in tumours developing drug resistance.
6 February 2020
Congratulations to Prof Kristijan Ramadan who has been awarded a three year research grant from Breast Cancer Now. The grant will support Dr. Abhay Narayan Singh who will explore new ways to use chemotherapy in order to improve the outcomes for women with breast cancer.
4 November 2019
The NIHR has invested £34 million of funding into global health research projects to tackle epilepsy, infection-related cancers and severe stigmatising skin diseases in low- and middle-income countries (LMICs).
20 September 2019
The Department of Oncology has signed up to collaborate with Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T cell enhancing therapeutics.
Clinical researchers at Oxford University announce new collaboration with Janssen to detect blood cancers sooner
8 August 2019
The new 7-year research collaboration with Janssen Research & Development, LLC (Janssen) will study patients at higher risk of developing certain types of blood cancers that arise from the immune system, such as chronic lymphocytic leukaemia and multiple myeloma, to identify markers that could be used to predict who will go on to develop symptomatic disease.